Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

Cora N Sternberg; Daniel P Petrylak; Oliver Sartor; J Alfred Witjes; Tomasz Demkow; Jean-Marc Ferrero; Jean-Christophe Eymard; Silvia Falcon; Fabio Calabrò; Nicholas James; Istvan Bodrogi; Peter Harper; Manfred Wirth; William Berry; Michael E Petrone; Thomas J McKearn; Mojtaba Noursalehi; Martine George; Marcel Rozencweig

doi:10.1200/JCO.2008.20.1228

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

Cora N Sternberg, Daniel P Petrylak, Oliver Sartor, J Alfred Witjes, Tomasz Demkow, Jean-Marc Ferrero, Jean-Christophe Eymard, Silvia Falcon, Fabio Calabrò, Nicholas James, Istvan Bodrogi, Peter Harper, Manfred Wirth, William Berry, Michael E Petrone, Thomas J McKearn, Mojtaba Noursalehi, Martine George, Marcel Rozencweig

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

257 Citations (Scopus)

Abstract

This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen.

Original language	English
Pages (from-to)	5431-8
Number of pages	8
Journal	Journal of Clinical Oncology
Volume	27
Issue number	32
DOIs	https://doi.org/10.1200/JCO.2008.20.1228
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2008.20.1228

Cite this

Sternberg, C. N., Petrylak, D. P., Sartor, O., Witjes, J. A., Demkow, T., Ferrero, J-M., Eymard, J-C., Falcon, S., Calabrò, F., James, N., Bodrogi, I., Harper, P., Wirth, M., Berry, W., Petrone, M. E., McKearn, T. J., Noursalehi, M., George, M., & Rozencweig, M. (2009). Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Journal of Clinical Oncology , 27(32), 5431-8. https://doi.org/10.1200/JCO.2008.20.1228

@article{6b919cc6ce504326b32498f6e1c05ccc,

title = "Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial",

abstract = "This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen.",

author = "Sternberg, {Cora N} and Petrylak, {Daniel P} and Oliver Sartor and Witjes, {J Alfred} and Tomasz Demkow and Jean-Marc Ferrero and Jean-Christophe Eymard and Silvia Falcon and Fabio Calabr{\`o} and Nicholas James and Istvan Bodrogi and Peter Harper and Manfred Wirth and William Berry and Petrone, {Michael E} and McKearn, {Thomas J} and Mojtaba Noursalehi and Martine George and Marcel Rozencweig",

year = "2009",

doi = "10.1200/JCO.2008.20.1228",

language = "English",

volume = "27",

pages = "5431--8",

journal = "Journal of Clinical Oncology ",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "32",

}

Sternberg, CN, Petrylak, DP, Sartor, O, Witjes, JA, Demkow, T, Ferrero, J-M, Eymard, J-C, Falcon, S, Calabrò, F, James, N, Bodrogi, I, Harper, P, Wirth, M, Berry, W, Petrone, ME, McKearn, TJ, Noursalehi, M, George, M & Rozencweig, M 2009, 'Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial', Journal of Clinical Oncology , vol. 27, no. 32, pp. 5431-8. https://doi.org/10.1200/JCO.2008.20.1228

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. / Sternberg, Cora N; Petrylak, Daniel P; Sartor, Oliver et al.
In: Journal of Clinical Oncology , Vol. 27, No. 32, 2009, p. 5431-8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy

T2 - the SPARC trial

AU - Sternberg, Cora N

AU - Petrylak, Daniel P

AU - Sartor, Oliver

AU - Witjes, J Alfred

AU - Demkow, Tomasz

AU - Ferrero, Jean-Marc

AU - Eymard, Jean-Christophe

AU - Falcon, Silvia

AU - Calabrò, Fabio

AU - James, Nicholas

AU - Bodrogi, Istvan

AU - Harper, Peter

AU - Wirth, Manfred

AU - Berry, William

AU - Petrone, Michael E

AU - McKearn, Thomas J

AU - Noursalehi, Mojtaba

AU - George, Martine

AU - Rozencweig, Marcel

PY - 2009

Y1 - 2009

N2 - This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen.

AB - This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen.

U2 - 10.1200/JCO.2008.20.1228

DO - 10.1200/JCO.2008.20.1228

M3 - Article

C2 - 19805692

SN - 1527-7755

VL - 27

SP - 5431

EP - 5438

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 32

ER -

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this